Gilead Data Shows Promise for Bictegravir/Lenacapavir Switch in HIV Treatment

Event summary

  • Phase 3 ARTISTRY-1 and ARTISTRY-2 trials demonstrated the efficacy of Gilead’s single-tablet regimen of bictegravir (75mg) and lenacapavir (50mg) (BIC/LEN) in patients switching from existing HIV therapies.
  • BIC/LEN showed non-inferiority to complex multi-tablet regimens and Gilead’s BIKTARVY® in maintaining virological suppression through Week 48.
  • The switch to BIC/LEN was associated with improvements in fasting lipid parameters and increased patient-reported treatment satisfaction.
  • Data was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2026 and published in The Lancet on February 25, 2026.

The big picture

Gilead's ARTISTRY trials highlight the ongoing need for improved HIV treatment options, particularly for patients experiencing intolerance or drug interactions with existing regimens. The data suggests BIC/LEN could offer a compelling alternative, potentially expanding Gilead’s market share within the $30 billion HIV therapeutics market. The combination’s novel mechanism of action, targeting the capsid protein, represents a strategic diversification of Gilead’s HIV portfolio beyond integrase inhibitors.

What we're watching

Regulatory Approval
The speed with which regulatory authorities review and potentially approve BIC/LEN will dictate the timeline for its market entry and impact Gilead’s revenue projections.
Market Adoption
How quickly physicians and patients adopt BIC/LEN as a switch option, particularly given the established efficacy and familiarity with BIKTARVY, will be crucial for its commercial success.
Resistance Profile
Continued monitoring of the emergence of resistance to lenacapavir, despite the current data showing no resistance, will be essential to ensure the long-term durability of the treatment.

Related topics

Drug Development